Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Castagnetti

Showing results (31-40 of 158) with videos related to

Pageof 16
Sort By:
The Lancet. Oncology|March 3, 2007
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALLSimona Soverini, Giovanni Martinelli, Sabrina Colarossi, et al.
Frontiers in Oncology|June 26, 2020
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid LeukemiaMario Annunziata, Massimiliano Bonifacio, Massimo Breccia, et al.
Haematologica|April 6, 2023
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemiaBenedetta Fiordi, Valentina Salvestrini, Gabriele Gugliotta, et al.
Plos One|December 17, 2013
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemiaElisa Leo, Manuela Mancini, Michela Aluigi, et al.
Cellular Signalling|May 28, 2013
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cellsManuela Mancini, Elisa Leo, Ken-Ichi Takemaru, et al.
Leukemia Research|June 16, 2009
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapyCarmen Baldazzi, Simona Luatti, Giulia Marzocchi, et al.
Haematologica|July 18, 2009
Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failureFrancesca Palandri, Fausto Castagnetti, Simona Soverini, et al.
Leukemia|March 26, 2022
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemiaMichele Baccarani, Francesca Bonifazi, Simona Soverini, et al.
Annals of Hematology|February 23, 2018
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatmentMassimo Breccia, Francesca Palandri, Luigiana Luciano, et al.
Haematologica|July 13, 2023
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II studyJorge E Cortes, Jeff H Lipton, Vamsi Kota, et al.
Pageof 16

Showing results (31-40 of 158) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|March 3, 2007
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALLSimona Soverini, Giovanni Martinelli, Sabrina Colarossi, et al.
Frontiers in Oncology|June 26, 2020
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid LeukemiaMario Annunziata, Massimiliano Bonifacio, Massimo Breccia, et al.
Haematologica|April 6, 2023
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemiaBenedetta Fiordi, Valentina Salvestrini, Gabriele Gugliotta, et al.
Plos One|December 17, 2013
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemiaElisa Leo, Manuela Mancini, Michela Aluigi, et al.
Cellular Signalling|May 28, 2013
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cellsManuela Mancini, Elisa Leo, Ken-Ichi Takemaru, et al.
Leukemia Research|June 16, 2009
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapyCarmen Baldazzi, Simona Luatti, Giulia Marzocchi, et al.
Haematologica|July 18, 2009
Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failureFrancesca Palandri, Fausto Castagnetti, Simona Soverini, et al.
Leukemia|March 26, 2022
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemiaMichele Baccarani, Francesca Bonifazi, Simona Soverini, et al.
Annals of Hematology|February 23, 2018
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatmentMassimo Breccia, Francesca Palandri, Luigiana Luciano, et al.
Haematologica|July 13, 2023
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II studyJorge E Cortes, Jeff H Lipton, Vamsi Kota, et al.
Pageof 16